News About: Pharm. Affairs
Vemlidy’s active competition in chronic hepatitis B treatment market
Gilead Sciences’ ‘Vemlidy Tab’ has entered general hospitals one after another, which raises an expectation on its sales performance in the future.
‘Vemlidy,’ a Gilead Sciences’ chronic hepatitis B treatment whose he...
AZ-NHIS’s dramatic conclusion on Tagrisso drug price negotiation
The AstraZeneca’s non-small cell lung cancer treatment Tagrisso(generic name: osimertinib), whose negotiation was broken down twice, finally passed the drug price negotiation.
The National Health Insurance Service(NH...
How far the Watson’s capability can go? It can be actively used in developing novel drugs
Watson, an IBM’s artificial intelligence computer, has been actively used in developing new drugs.
At the ‘KoNECT International Conference’ on the 2nd, Dr. Alice Landis-McGrath at IBM said “In order to discover medic...
“Clinical trials must be conducted in order based on ‘social values’”
An opinion was suggested that studies must be performed with regional priority after considering social contexts before conducting them.
“A thing to remember when conducting a clinical trial ” Vice President Kathy Ro...
Gilead Sciences’ chronic hepatitis B treatment Vemlidy with health insurance benefits
Vemlidy(generic name: Tenofovir Alafenamide Fumarate), a Gilead Sciences Korea’s(CEO Seung-Woo Lee) chronic hepatitis B treatment, will receive the national health insurance benefits from the 1st of November.
Vemlidy...
Ibrance decided for the health insurance benefit while Olita Tab to be decided later after Phase III clinical trial
The patient sharing amount for Pfizer Pharmaceuticals Korea’s Ibrance Cap(palbociclib) will be reduced from KRW 5 million to KRW 150 thousand with approval of the national health insurance service(NHIS).
Hanmi Pharm’...
‘Tamifly’ generics approved the most with 122 products this year
A substance which made the highest number of generics this year was oseltamivir phosphate(product name: Tamiflu) with 122 products.
According to the Ministry of Food and Drug Safety, the number of medicines approved...
Unstoppable antidiabetic ‘Zemiglo’ passing KRW 7 billion prescriptions a month
‘Zemiglo,’ a novel antidiabetic developed for the first time in Korea, passed KRW 7 billion prescriptions a month.
According to UBIST, a pharmaceutical information company, LG Chem’s ‘Zemiglo’ passed KRW 7 billion ou...
66 pharmacies increased in Seoul this year, 15 pharmacies only in Gangnam-gu
This year, the number of pharmacies in the Seoul area was increased by 66, and 15 of them were only in Gangnam-gu. Also, Gamgnam-gu(420 pharmacies)) had about 3 times more pharmacies than Dobong-gu(118 pharmacies), a ...
Insurance Benefit Evaluation Committee assesses benefit for ‘Rupapin Tab’ and conditional uninsured for ‘Edarbi Tab’
The Health Insurance Review & Assessment Service Health Insurance Benefit Evaluation Committee held a meeting on the 27th and assessed propriety for health insurance benefits on 10 companies’ 15 products.
According t...
